ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.177,62
-0,90%
S&P 500
5.469,30
0,39%
Dow Jones
39.112,16
-0,76%
Euro vs US Dollar
1,07048
-0,04%
Bitcoin
61.635,96
-0,28%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Spyre Therapeutics Inc (SYRE)

  7. Spyre Therapeutics Inc (SYRE) News

SYRE

Spyre Therapeutics (SYRE)

Spyre Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SYRE
DatumZeitQuelleÜberschriftSymbolFirma
18/06/202413h30PR Newswire (US)Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel DiseaseNASDAQ:SYRESpyre Therapeutics Inc
03/06/202423h23PR Newswire (US)Spyre Therapeutics Announces Grants of Inducement AwardsNASDAQ:SYRESpyre Therapeutics Inc
30/05/202422h33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRESpyre Therapeutics Inc
29/05/202414h30PR Newswire (US)Spyre Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:SYRESpyre Therapeutics Inc
16/05/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
16/05/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
16/05/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
16/05/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
16/05/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
16/05/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
16/05/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
16/05/202422h05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
15/05/202413h40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRESpyre Therapeutics Inc
15/05/202413h30PR Newswire (US)Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of DirectorsNASDAQ:SYRESpyre Therapeutics Inc
09/05/202422h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRESpyre Therapeutics Inc
09/05/202422h08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SYRESpyre Therapeutics Inc
09/05/202422h02PR Newswire (US)Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:SYRESpyre Therapeutics Inc
03/05/202423h00PR Newswire (US)Spyre Therapeutics Announces Grants of Inducement AwardsNASDAQ:SYRESpyre Therapeutics Inc
01/04/202423h00PR Newswire (US)Spyre Therapeutics Announces Grants of Inducement AwardsNASDAQ:SYRESpyre Therapeutics Inc
18/03/202413h00PR Newswire (US)Spyre Therapeutics Announces $180 Million Private PlacementNASDAQ:SYRESpyre Therapeutics Inc
05/03/202423h15Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:SYRESpyre Therapeutics Inc
01/03/202423h25PR Newswire (US)Spyre Therapeutics Announces Grants of Inducement AwardsNASDAQ:SYRESpyre Therapeutics Inc
01/03/202412h14Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
29/02/202423h06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SYRESpyre Therapeutics Inc
29/02/202422h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRESpyre Therapeutics Inc
29/02/202422h05PR Newswire (US)Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:SYRESpyre Therapeutics Inc
26/02/202413h30PR Newswire (US)Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care ConferenceNASDAQ:SYRESpyre Therapeutics Inc
21/02/202403h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
15/02/202402h47Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
14/02/202422h05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SYRE

Kürzlich von Ihnen besucht

USOTC
ADDYY
Adidas (QX)
TG
TUI1
Tui
DBI
TDXP
Tec DAX
CCOM
US500
US 500
TG
LHA
Deutsche Lufthansa
DBI
MDAX
MDAX
AMEX
XLV
Health Care Select Sector
NYSE
MCD
McDonalds
DBI
SDXP
SDAX
FX
EURJPY
Euro vs Yen
TG
RHM
Rheinmetall
USOTC
RHHBY
Roche (QX)
NASDAQ
MSFT
Microsoft
USOTC
BASFY
BASF (QX)
NYSE
KO
Coca Cola
TG
DTE
Deutsche Telekom
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten